Blueprint Medicines News and Activities

Blueprint Medicines is owned by Sanofi.

Sanofi is one of the...

• CAC 40;
• CAC All-Trade;
• Forbes Global 2000 (#131);
• Fortune 500 Europe (#74);
• Global Fortune 500 (#277);
• SBF 120;
• Stoxx 600;
• TOB Iconic 10,000.

Sanofi is a company listed under the stock ticker SAN (FR).

Sanofi has a direct presence in 33 countries.

Sanofi has 46 subsidiaries including Blueprint Medicines, Euroapi and Genzyme Denmark.

They are in:

• Pharmaceuticals94%
• Biotechnology4%
• Other2%

Acquisition, funding and merger involving Sanofi.

• Blueprint Medicines and Sanofi have merged  (posted on July 21 2025)..
• Sanofi has announced the acquisition of Blueprint Medicines  (posted on June 2 2025).

View the org chart displaying its 8 main executives

Most searched biographies at Blueprint Medicines

• Percy Carter, Chief Scientific Officer
• Lauren Barnes, Senior Vice President, Strategic Market Development...
• Csani Varga, Senior Vice President, Pharmaceutical Sciences & Manu...

Popular executive movements at Blueprint Medicines

• Kate Haviland, Director, President and Chief Executive Officer, has left the company  (posted on February 23 2026).
• Becker Hewes, Chief Medical Officer, has left the company  (posted on January 7 2026).
• Christina Rossi, Chief Operating Officer, has left the company  (posted on November 26 2025).

Click here to view some more movements at Blueprint Medicines

Popular executive movements at Sanofi

• Christel Heydemann has joined the company as Director  (posted on May 7 2026).
• Emy Rossi, Head of Talent Management Global Corporate Functions, has left the company  (posted on April 23 2026).
• Fabrizio Guidi, Head, Go To Market Capabilities, has left the company  (posted on April 23 2026).

Click here to view some more movements at Sanofi

Create your alert
to follow the executive moves at Blueprint Medicines.

Sanofi has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Blueprint Medicines

• Blueprint Medicines Reports Second Quarter 2022 Results | Blueprint Medicines Corp.
• Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 | Blueprint Medicines Corp.
• Blueprint Medicines Publishes Inaugural Corporate Responsibility Report | Blueprint Medicines Corp.
• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Blueprint Medicines Corp.
• Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma | Blueprint Medicines Corp.
• Blueprint Medicines Appoints Habib Dable to its Board of Directors | Blueprint Medicines Corp.
• Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis | Blueprint Medicines Corp.
• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Blueprint Medicines Corp.
• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Blueprint Medicines Corp.
• Blueprint Medicines Reports First Quarter 2022 Results | Blueprint Medicines Corp.
• View more press releases Close

Social media about Blueprint Medicines

• Blueprint Medicines on Wikipedia, Google News & Yahoo Finance
• Blueprint Medicines on LinkedIn, X (Twitter) & YouTube